Cantor Fitzgerald Has Negative View of Amgen FY2025 Earnings

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Amgen in a research report issued on Wednesday, February 5th. Cantor Fitzgerald analyst O. Brayer now anticipates that the medical research company will post earnings of $20.67 per share for the year, down from their prior forecast of $21.44. Cantor Fitzgerald has a “Overweight” rating and a $405.00 price objective on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.56 per share.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%.

Several other research analysts have also weighed in on AMGN. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Bank of America boosted their price target on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Finally, Piper Sandler cut their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $314.83.

Amgen Trading Up 6.5 %

Shares of AMGN opened at $307.81 on Thursday. Amgen has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market cap of $165.46 billion, a PE ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The stock has a 50 day simple moving average of $271.69 and a 200-day simple moving average of $303.55. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.09%. Amgen’s payout ratio is presently 115.24%.

Institutional Investors Weigh In On Amgen

Institutional investors and hedge funds have recently made changes to their positions in the business. AMF Tjanstepension AB lifted its position in Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after acquiring an additional 17,387 shares in the last quarter. Czech National Bank lifted its stake in Amgen by 7.1% in the 3rd quarter. Czech National Bank now owns 109,459 shares of the medical research company’s stock worth $35,269,000 after purchasing an additional 7,237 shares in the last quarter. City Center Advisors LLC bought a new stake in Amgen during the third quarter valued at approximately $220,000. Atomi Financial Group Inc. increased its position in shares of Amgen by 4.2% during the 3rd quarter. Atomi Financial Group Inc. now owns 5,388 shares of the medical research company’s stock valued at $1,736,000 after purchasing an additional 217 shares during the last quarter. Finally, City Holding Co. grew its position in Amgen by 0.6% during the 3rd quarter. City Holding Co. now owns 10,719 shares of the medical research company’s stock worth $3,454,000 after acquiring an additional 67 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.